Title of article :
Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
Author/Authors :
Wang, Bin Department of Epidemiology and Biostatistics - School of Public Health - Anhui Medical University - Anhui Province Key Laboratory of Major Autoimmune Diseases - Anhui - China , Lu, Jin- Sen Department of Epidemiology and Biostatistics - School of Public Health - Anhui Medical University - Anhui Province Key Laboratory of Major Autoimmune Diseases - Anhui - China , Wang, Zhi- Hui Department of Epidemiology and Biostatistics - School of Public Health - Anhui Medical University - Anhui Province Key Laboratory of Major Autoimmune Diseases - Anhui - China , Wang, Hong Department of Epidemiology and Biostatistics - School of Public Health - Anhui Medical University - Anhui Province Key Laboratory of Major Autoimmune Diseases - Anhui - China
Abstract :
We read the article entitled “Association of CYP2C19
and ABCB1 polymorphisms with clopidogrel resistance in
clopidogrel-treated Chinese patients” by Zhuo et al. (1) published
in Anatol J Cardiol 2018; 19: 123-9. It is highly appreciated that
there is an increasing number of researches to explore the
paradigm of gene polymorphisms behind abnormal clinical
manifestations, especially for drug resistance, because a variety
of problems were encountered during the large-scale use of
many classical drugs (2). As an ideal adenosine diphosphate
(ADP) receptor antagonist with quick effects and high security,
clopidogrel has been widely used in the prevention of myocardial
infarction, stroke, atherosclerosis, and other related diseases for
several years; however, at the same time, clopidogrel resistance
has brought much trouble to classical ischemic events (3)
Keywords :
CYP2C19 , ABCB1 polymorphisms , clopidogrel resistance , clopidogrel-treated Chinese patients
Journal title :
The Anatolian Journal of Cardiology: Andolu Kardiyoloji Dergisi
